Z-Asp-CH2-DCB

Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB) -stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development[1][2][3].

Product Specifications

CAS Number

[153088-73-4]

Product Name Alternative

MSC2363318A

UNSPSC

12352005

Target

Apoptosis; Caspase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Neuroscience-Neurodegeneration

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/z-asp-ch2-dcb.html

Purity

99.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(O)=O)=O)C2=C(Cl)C=CC=C2Cl

Molecular Formula

C20H17Cl2NO7

Molecular Weight

454.26

References & Citations

[1]Krakauer T, et al. Caspase inhibitors attenuate superantigen-induced inflammatory cytokines, chemokines, and T-cell proliferation. Clin Diagn Lab Immunol. 2004 May;11 (3) :621-4.|[2]Kasahara Y, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000 Dec;106 (11) :1311-9.|[3]Twumasi P, et al. Caspase inhibitors affect the kinetics and dimensions of tracheary elements in xylogenic Zinnia (Zinnia elegans) cell cultures. BMC Plant Biol. 2010 Aug 6;10:162.